Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: A time-series analysis for France 1998-2010

Health Policy

Volumn 102, Issue 2-3, 2011, Pages 159-169

  Pichetti, Sylvain ^a   Sorasith, Christine ^a   Sermet, Catherine ^a  

^a Institut de Recherche et de Documentation en Economie de la Santé Irdes   (France)

Author keywords

Drug costs; France; Linear segmented regression; Mucolytics; Pharmaceuticals; Reimbursement

Indexed keywords

ANTIINFECTIVE AGENT; ANTITUSSIVE AGENT; BRONCHODILATING AGENT; EXPECTORANT AGENT; MUCOLYTIC AGENT;

ARTICLE; DRUG COST; FRANCE; HEALTH CARE COST; HEALTH INSURANCE; PHYSICIAN; POLICY; PRESCRIPTION; QUESTIONNAIRE; REIMBURSEMENT;

ANTITUSSIVE AGENTS; BRONCHODILATOR AGENTS; COST SAVINGS; DRUG COSTS; EXPECTORANTS; FRANCE; HEALTH CARE REFORM; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LINEAR MODELS; PRESCRIPTION DRUGS; PUBLIC HEALTH;

EID: 80052796623     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2011.07.001     Document Type: Article

References (34)

1. Dormont B., Grignon M., Huber H. Health expenditure growth: reassessing the threat of ageing. Health Economy 2006, 15(September (9)):947-963.
2. Nuijten M.J.C., Berto P., Berdeaux G., Hutton J., Fricke F.U. Trends in decision-making process for pharmaceuticals in Western European countries. Hepac: Health Economics in Prevention and Care 2001, 2(4):162-169.
3. Rocchi F., Addis A., Martini N. Current national initiatives about drug policies and cost control in Europe: the Italy example. Journal of Ambulance Care Management 2004, 27(April (2)):127-131.
4. Ess S.M., Schneeweiss S., Szucs T.D. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003, 21(2):89-103.
5. Godman B., Shrank W., Andersen M., Berg C., Bishop I., Burkhardt T., et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Review Pharmacoeconomics Outcomes Research 2010, 10(December (6)):707-722.
6. Goldman D.P., Joyce G.F., Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007, 298(July (1)):61-69.
7. Gibson T.B., Ozminkowski R.J., Goetzel R.Z. The effects of prescription drug cost sharing: a review of the evidence. The American Journal of Managed Care 2005, 11(November (11)):730-740.
8. Anis A.H., Guh D.P., Lacaille D., Marra C.A., Rashidi A.A., Li X., et al. When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions. CMAJ 2005, 173(November (11)):1335-1340.
9. Allegra C. Chronic venous insufficiency: the effects of health-care reforms on the cost of treatment and hospitalisation-an Italian perspective. Current Medical Research and Opinion 2003, 19(8):761-769.
10. Leibowitz A. Substitution between prescribed and over-the-counter medications. Medical Care 1989, 27(January (1)):85-94.
11. Green C.J., Maclure M., Fortin P.M., Ramsay C.R., Aaserud M., Bardal S. Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Database of Systematic Reviews 2010, 8:CD008654.
12. Godwin M., Chapman J., Mowat D., Racz W., McBride J., Tang J. Delisting of drugs in Ontario. How attitudes and prescribing strategies of family physicians in the Kingston area changed. Canadian Family Physician 1996, 42(July):1309-1316.
13. Meissner B., Dickson M., Shinogle J., Reeder C.E., Belazi D., Senevirante V. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. Journal of Managed Care Pharmacy 2006, 12(May (4)):331-340.
14. Gur A.O., Topaler B. How removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives. The European Journal of Health Economics 2010, [August 18].
15. Soumerai S.B., Ross-Degnan D., Gortmaker S., Avorn J. Withdrawing payment for nonscientific drug therapy. Intended and unexpected effects of a large-scale natural experiment. JAMA 1990, 263(February (6)):831-839.
16. Sketris I.S., Kephart G.C., Frail D.M., Skedgel C., Allen M.J. The effect of deinsuring chlorpropamide on the prescribing of oral antihyperglycemics for Nova Scotia Seniors' Pharmacare beneficiaries. Pharmacotherapy 2004, 24(June (6)):784-791.
17. Devaux M, Grandfils N, Sermet C. Déremboursement des mucolytiques et des expectorants: quel impact sur la prescription des généralistes? 2007. p. 1-6.
18. Sabuncu E., David J., Bernede-Bauduin C., Pepin S., Leroy M., Boelle P.Y., et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Medicine 2009, 6(June (6)):e1000084.
19. Wagner A.K., Soumerai S.B., Zhang F., Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics 2002, 27(August (4)):299-309.
20. Dickey D.A., Fuller W.A. Distribution of the estimators for autoregressive time series with a unit root. Journal of The American Statistical Association 1979, 74(366):427-431.
21. Zhang F., Wagner A., Soumerai S.B., Ross-Degnan D. Estimating confidence intervals around relative changes in outcomes in segmented regression. Analyses of Time Series Data 2002.
22. Kephart G., Sketris I.S., Bowles S.K., Richard M.E., Cooke C.A. Impact of a criteria-based reimbursement policy on the use of respiratory drugs delivered by nebulizer and health care services utilization in Nova Scotia, Canada. Pharmacotherapy 2005, 25(September (9)):1248-1257.
23. Marshall D., Gough J., Grootendorst P., Buitendyk M., Jaszewski B., Simonyi S., et al. Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis. Journal of Health Services Research and Policy 2006, 11(January (1)):13-20.
24. Wettermark B., Godman B., Neovius M., Hedberg N., Mellgren T.O., Kahan T. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 2010, 94(March (3)):221-229.
25. Amar E., Pereira C. Evolution des ventes de médicaments suite aux changements de leur conditions de remboursement. Solidarite Sante-Etudes Statistiques 2004, 3:57-77.
26. Anonymous Déremboursements post-réévaluation. La Revue Prescrire 2006, 26(271):258-260.
27. Poole P.J., Black P.N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001, 322(May (7297)):1271-1274.
28. Lu C.Y., Soumerai S.B., Ross-Degnan D., Zhang F., Adams A.S. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Medical Care 2010, 48(January (1)):4-9.
29. Puig-Junoy J. The impact of generic reference pricing interventions in the statin market. Health Policy 2007, 84(November (1)):14-29.
30. Eccles R. Importance of placebo effect in cough clinical trials. Lung 2010, 188(January (Suppl. 1)):S53-S61.
31. Schroeder K., Fahey T. Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Systematic Reviews 2004, (4):CD001831.
32. Delga C., Megnin Y., Oustric S., Laurent C., Pauly L., Vergez J.P., et al. A pilot study in general practice: pressure to prescribe. Therapie 2003, 58(November (6)):513-517.
33. Soumerai S.B., Ross-Degnan D., Fortess E.E. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. The Milbank Quarterly 1993, 71(2):217-252.
34. Anonymous Impact économique des conditions de remboursement des SMRi en 2006. La Mutualité Française 2007.